A PHASE I DOSE-ESCALATION STUDY OF MPEG-R-CRISANTASPASE ADMINISTERED BY INTRAVENOUS INFUSION IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES

被引：0
|
作者：
Salles, G. [1 ]
Lepretre, S. [2 ]
Le Gouill, S. [3 ]
Rigal-Huguet, F. [4 ]
Haioun, C. [5 ]
Balouet, S. [6 ]
Corn, T. [7 ]
Thomas, X. [1 ]
机构：
[1] Univ Lyon 1, Hosp Civils Lyon, Pierre Benite, France
[2] Ctr Henri Becquerel, F-76038 Rouen, France
[3] CHU Nantes, F-44035 Nantes 01, France
[4] Ctr Hosp Univ Toulouse, Toulouse, France
[5] Ctr Hosp Univ Henri Mondor, Creteil, France
[6] Lymphoma Acad Res Org LYSARC, Pierre Benite, France
[7] EUSA Pharma, Oxford, England
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P771
引用
收藏
页码：279 / 279
页数：1
相关论文
共 50 条
  • [1] A PHASE I DOSE-ESCALATION STUDY OF PEGCRISANTASPASE ADMINISTERED BY INTRAVENOUS INFUSION IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES
    Salles, G.
    Lepretre, S.
    Le Gouill, S.
    Rigal-Huguet, F.
    Haioun, C.
    Balouet, S.
    Corn, T.
    Thomas, X.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S209 - S209
  • [2] Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
    Sekiguchi, Naohiro
    Kasahara, Senji
    Miyamoto, Toshihiro
    Kiguchi, Toru
    Ohno, Hitoshi
    Takagi, Taiga
    Tachibana, Masaya
    Sumi, Hiroyuki
    Kakurai, Yasuyuki
    Yamashita, Tomonari
    Usuki, Kensuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (01) : 68 - 77
  • [3] Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
    Naohiro Sekiguchi
    Senji Kasahara
    Toshihiro Miyamoto
    Toru Kiguchi
    Hitoshi Ohno
    Taiga Takagi
    Masaya Tachibana
    Hiroyuki Sumi
    Yasuyuki Kakurai
    Tomonari Yamashita
    Kensuke Usuki
    International Journal of Hematology, 2023, 117 : 68 - 77
  • [4] Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
    Lokhorst, Henk M.
    Plesner, Torben
    Gimsing, Peter
    Nahi, Hareth
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Laubach, Jacob
    Lisby, Steen
    Basse, Linda
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] A PHASE I DOSE-ESCALATION OF LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Wendtner, C. M.
    Mahadevan, D.
    Coutre, S.
    Hillmen, P.
    Stilgenbauer, S.
    Frankfurt, O.
    Bloor, A.
    Bosch, F.
    Furman, R.
    Uharek, L.
    Kimby, E.
    Gobbi, M.
    Dreisback, L.
    Hurd, D.
    Sekeres, M.
    Gribben, J.
    Shah, S.
    Parseval, L. Moutouh-de
    Chanan-Khan, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 371 - 372
  • [6] Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies
    Hatake, Kiyohiko
    Chou, Takaaki
    Doi, Toshihiko
    Terui, Yasuhito
    Kato, Harumi
    Hirose, Takayuki
    Seo, Sachiko
    Pourdehnad, Michael
    Ogaki, Yumi
    Fujimoto, Hiroshi
    Hagner, Patrick R.
    Yamamoto, Kazuhito
    CANCER SCIENCE, 2021, 112 (01) : 331 - 338
  • [7] Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma.
    Lust, John Anthony
    Barranco, Charles
    Lacy, Martha
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen J.
    Buadi, Francis
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji
    Usmani, Saad Zafar
    Thompson, John
    Taylor, Catherine
    Dondero, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
    M Brada
    I Judson
    P Beale
    S Moore
    P Reidenberg
    P Statkevich
    M Dugan
    V Batra
    D Cutler
    British Journal of Cancer, 1999, 81 : 1022 - 1030
  • [9] Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
    Brada, M
    Judson, I
    Beale, P
    Moore, S
    Reidenberg, P
    Statkevich, P
    Dugan, M
    Batra, V
    Cutler, D
    BRITISH JOURNAL OF CANCER, 1999, 81 (06) : 1022 - 1030
  • [10] Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
    Rixe, Olivier
    Puzanov, Igor
    LoRusso, Patricia M.
    Cohen, Roger B.
    Morris, John C.
    Olowokure, Olugbenga O.
    Yin, Jian Y.
    Doroumian, Severine
    Shen, Liji
    Olszanski, Anthony J.
    ANTI-CANCER DRUGS, 2015, 26 (07) : 785 - 792
12345